|Bid||3.2300 x 1400|
|Ask||3.2400 x 1100|
|Day's Range||3.1400 - 3.3000|
|52 Week Range||1.4200 - 4.8300|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.
Selecta Biosciences, Inc. (NASDAQ:SELB) shareholders will have a reason to smile today, with the analysts making...
For opening remarks, I would like to turn it to Brad Dahms, Chief Financial Officer of Selecta. The press release reporting our financial results is available in the Investors & Media section of our website www.selectabio.com and our quarterly report on Form 10-Q for the quarter ended September 30, 2020 will be filed later on today with the SEC. Joining me today is Carsten Brunn, our President and CEO; and Dr. Peter Traber, our Chief Medical Officer.